Sign Up Today and Learn More About Primmune Therapeutics Stock
Invest in or calculate the value of your shares in Primmune Therapeutics or other pre-IPO companies through EquityZen's platform.
Primmune Therapeutics Stock
Primmune Therapeutics is a Biotechnology company.
About Primmune Therapeutics Stock
Founded
2017
Headquarters
San Diego, CA, US
Industries
Travel and Tourism, Space, Transportation
Primmune Therapeutics Press Mentions
Stay in the know about the latest news on Primmune Therapeutics
Primmune Therapeutics Raises $8.6M in Additional Series B Funding
finsmes • Jan 31, 2026
Primmune Therapeutics Announces Additional Close of Series B Financing
vcaonline • Jan 29, 2026
Primmune Therapeutics Announces Additional Close of Series B Financing
biospace • Jan 28, 2026
Primmune Therapeutics Announces Additional Close of Series B Financing
sdbn • Jan 28, 2026
Primmune Therapeutics Announces Additional Close of Series B Financing
globenewswire • Jan 26, 2026
Primmune Therapeutics Management
Leadership team at Primmune Therapeutics
Board Member
Scott Morenstein
Board Member
Debbie Dumont
Join now and verify your accreditation status to gain access to:
- Primmune Therapeutics Current Valuation
- Primmune Therapeutics Stock Price
- Primmune Therapeutics Management
- Available deals in Primmune Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Primmune Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Primmune Therapeutics Revenue and Financials
- Primmune Therapeutics Highlights
- Primmune Therapeutics Business Model
- Primmune Therapeutics Risk Factors
- Primmune Therapeutics Research Report from SACRA Research
Trading Primmune Therapeutics Stock
How to invest in Primmune Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Primmune Therapeutics through EquityZen funds. These investments are made available by existing Primmune Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Primmune Therapeutics stock?
Shareholders can sell their Primmune Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 420K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."